Market Overview

PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

Share:
PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

Polarityte Inc (NASDAQ: PTE) shares were seeing an upward bounce Monday in reaction to a clinical trial readout at the American Diabetes Association's 79th Scientific Sessions conference.

What Happened

PolarityTE presented final results from a pilot study on the use of its SkinTE product for hard-to-treat diabetic foot ulcers, or DFUs, as a poster, which showed that 10 of the 11 patients evaluated in the study had healed DFUs within eight weeks of SkinTE application, with a mean time to heal of 29.7 days.

SkinTE is an autologous, homologous human cellular and tissue-based product capable of regenerating full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin.

One patient was removed from the study at week three due to adverse events not related to the study or SkinTE procedure, the company said. 

Why It's Important

Despite the presence of numerous products in the market, DFUs are challenging for patients, as most treatments do not produce good outcomes.

"In this study, some of the most challenging wounds in the chronic wound-care market healed after a single application of SkinTE, where other standard treatments had failed," PolarityTE Chief Scientific Officer Nikolai Sopko said in a statement. 

What Next

PolaityTE said the abstract will be published in the online supplement to the journal Diabetes later this year.

The stock was trading higher by 10.27 percent at $6.44 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Sanofi's Leadership Transition: What You Need To Know

Posted-In: Citron ResearchBiotech News Short Sellers Trading Ideas General Best of Benzinga

 

Related Articles (PTE)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Trump Talks China, Mexico And Big Tech In CNBC Interview

Missouri's Medical Cannabis Program Proceeding Apace